Merck Serono's Safinamide Significantly Improved Motor Function in Patients With Advanced Parkinson's Disease in a Phase III Pivotal Trial
GENEVA, Feb. 3 /PRNewswire/ --
-- The Six-Month Primary Efficacy Endpoint of the Study was met: Both
Doses of Investigational Agent Safinamide
Significantly Increased "ON" Time in
Levodopa-Treated Patients With mid- to Late-Stage Parkinson's Disease
-- Secondary Efficacy Endpoi...
Phase III Data on Safinamide in Parkinson’s Disease Presented
at American Academy of Neurology 59th Annual Meeting
GENEVA, Switzerland, May 2, 2007 – Merck
Serono S.A. (virt-x: SEO) announced today that Phase III data on
safinamide, a new agent in Phase III development for the treatment
of Parkinson’s disease symptoms, were presented by Professor
Fabrizio Stocchi at the American Academy of Neur...
Promising Data on Cognitive Effects of Safinamide in Early
• Data presented at Movement Disorder Society’s 11th
• Management of cognitive impairment in early
Parkinson’s disease patients is a critical unmet medical
Geneva, Switzerland, June 8, 2007 – Merck Serono S.A.
(virt-x: SEO) and its partne...
Merck Serono Announces Presentation of Phase III Clinical Data on
Safinamide in Parkinson’s Disease at the American Academy of
Neurology 59th Annual Meeting
...resent the results of the first
Phase III trial of safinamide
as an adjunctive treatment to
dopamine agonists (D...e rights to
develop, manufacture and commercialise safinamide
Merck Serono 9 Chemin des Mines Corporate .... Recent
results of a six-month phase III trial of safinamide
demonstrated its benefit in motor symptoms a...